From molecule to market access, better decisions start with better models.
Pharmaeconomica helps pharma, biotech, research institutions, and investors reduce uncertainty across discovery, evidence, and access decisions through predictive modeling, HEOR, market access strategy, and AI-enabled drug discovery.
Experience
Experience with leading healthcare and life sciences organizations.
Pharmaeconomica’s expertise is grounded in practical work across pharma, medtech, consulting, market access, and evidence strategy.
What we do
We connect evidence, modeling, access, and AI discovery.
Pharmaeconomica is built around a common strategic capability: using evidence and predictive models to support high-stakes life sciences decisions.
Evidence & HEOR
Health economics, evidence synthesis, evidence gap assessment, value communication, and modeling support for development and access decisions.
Market Access & Reimbursement
Pricing, reimbursement, payer evidence planning, HTA strategy, and access roadmaps for life sciences assets.
Predictive Modeling & Simulation
Scenario modeling, uncertainty analysis, predictive analytics, health economic models, and decision-support frameworks.
AI-Enabled Discovery
Target-based predictive screening, ADMET and developability triage, candidate prioritization, and PreditX®-enabled discovery workflows.
Why Pharmaeconomica
One decision-science logic across the life sciences value chain.
Early discovery and market access may look separate, but both depend on the same questions: what evidence exists, what is uncertain, what should be prioritized, and what future value can be predicted.
PreditX® extends our predictive modeling approach into early discovery.
PreditX® is Pharmaeconomica’s cloud-native AI discovery platform for target-based predictive screening, ADMET and developability triage, consensus prediction reports, and small-molecule candidate prioritization.
Generative AI is being developed as an expansion around the predictive core.
Visit PreditXPlatform capability
Target-based predictive screening and candidate prioritization.
Services
Expert support for evidence, access, and innovation decisions.
HEOR & health economics
Pricing and reimbursement strategy
Market access planning
Evidence generation and literature reviews
Predictive modeling and simulation
AI-enabled drug discovery strategy
News
Recent updates
Platform milestone
PreditX® registered as EU trademark
Innovation funding
VLAIO feasibility project completed
Discovery program
Selective BChE inhibitor compounds identified
Contact
Ready to discuss your evidence, market access, or AI discovery strategy?
Contact Pharmaeconomica to explore how predictive modeling, evidence generation, HEOR, market access strategy, or PreditX® can support your next life sciences decision.
info@pharmaeconomica.com